EP0338062A1 - Durch sprühen verabreichtes arzneimittel auf basis einer kombination aus polymixin b, tobramycin und amphotericin b - Google Patents
Durch sprühen verabreichtes arzneimittel auf basis einer kombination aus polymixin b, tobramycin und amphotericin bInfo
- Publication number
- EP0338062A1 EP0338062A1 EP19880909559 EP88909559A EP0338062A1 EP 0338062 A1 EP0338062 A1 EP 0338062A1 EP 19880909559 EP19880909559 EP 19880909559 EP 88909559 A EP88909559 A EP 88909559A EP 0338062 A1 EP0338062 A1 EP 0338062A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- administered
- precise
- amphotericin
- polymyxin
- tobramycin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 239000003814 drug Substances 0.000 title claims abstract description 10
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 title claims abstract description 7
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 title claims abstract description 7
- 229960003942 amphotericin b Drugs 0.000 title claims abstract description 7
- 238000005507 spraying Methods 0.000 title claims abstract description 7
- 229940079593 drug Drugs 0.000 title claims abstract description 6
- 229960005266 polymyxin b Drugs 0.000 title claims abstract description 6
- 229960000707 tobramycin Drugs 0.000 title claims abstract description 6
- NLVFBUXFDBBNBW-PBSUHMDJSA-N tobramycin Chemical compound N[C@@H]1C[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N NLVFBUXFDBBNBW-PBSUHMDJSA-N 0.000 title claims abstract description 6
- ZBJNZFQKYZCUJU-PAHFEQBRSA-N N-[(2S)-4-amino-1-[[(2S,3R)-1-[[(2S)-4-amino-1-oxo-1-[[(3S,6S,9S,12S,15R,18R,21S)-6,9,18-tris(2-aminoethyl)-15-benzyl-3-[(1R)-1-hydroxyethyl]-12-(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxobutan-2-yl]-6-methylheptanamide (6S)-N-[(2S)-4-amino-1-[[(2S,3R)-1-[[(2S)-4-amino-1-oxo-1-[[(3S,6S,9S,12S,15R,18R,21S)-6,9,18-tris(2-aminoethyl)-15-benzyl-3-[(1R)-1-hydroxyethyl]-12-(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxobutan-2-yl]-6-methyloctanamide Polymers CC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@@H](CCN)NC1=O)[C@@H](C)O.CC[C@H](C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@@H](CCN)NC1=O)[C@@H](C)O ZBJNZFQKYZCUJU-PAHFEQBRSA-N 0.000 title 1
- 239000003242 anti bacterial agent Substances 0.000 claims abstract description 8
- 229940088710 antibiotic agent Drugs 0.000 claims abstract description 8
- 238000009834 vaporization Methods 0.000 claims abstract description 6
- 230000008016 vaporization Effects 0.000 claims abstract description 6
- 108010093965 Polymyxin B Proteins 0.000 claims abstract description 5
- 229920000024 polymyxin B Polymers 0.000 claims abstract description 5
- 208000015181 infectious disease Diseases 0.000 claims abstract description 4
- 239000000443 aerosol Substances 0.000 claims abstract description 3
- 238000002663 nebulization Methods 0.000 claims abstract description 3
- 238000002360 preparation method Methods 0.000 claims description 6
- 244000052616 bacterial pathogen Species 0.000 claims 1
- 206010017533 Fungal infection Diseases 0.000 abstract description 4
- 206010060976 Bacillus infection Diseases 0.000 abstract description 2
- 241000304886 Bacilli Species 0.000 abstract 1
- 210000003928 nasal cavity Anatomy 0.000 abstract 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 210000004400 mucous membrane Anatomy 0.000 description 2
- ZEUUPKVZFKBXPW-TWDWGCDDSA-N (2s,3r,4s,5s,6r)-4-amino-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2r,3r,5s,6r)-3-amino-6-(aminomethyl)-5-hydroxyoxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-6-(hydroxymethyl)oxane-3,5-diol;sulfuric acid Chemical compound OS(O)(=O)=O.N[C@@H]1C[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N ZEUUPKVZFKBXPW-TWDWGCDDSA-N 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 235000006679 Mentha X verticillata Nutrition 0.000 description 1
- 235000002899 Mentha suaveolens Nutrition 0.000 description 1
- 235000001636 Mentha x rotundifolia Nutrition 0.000 description 1
- 108010040201 Polymyxins Proteins 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 238000005202 decontamination Methods 0.000 description 1
- 230000003588 decontaminative effect Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 208000024386 fungal infectious disease Diseases 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 229960004477 tobramycin sulfate Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
Definitions
- the present invention relates to a spray medication intended to prevent the risks of infection in patients at risk by decontaminating the nasal and oropharyngeal cavities.
- Gram-negative bacillus infections and yeast infections are common in at-risk patients. They cause significant morbidity, they are one of the main causes of the death of these patients, they increase health expenditure by increasing the length of hospital stay.
- the present invention overcomes this drawback. It includes the combination of three antibiotics administered by spraying into the nasal and oropharyngeal cavities.
- the three antibiotics associated in the preparation are polymyxin B, tobramycin and amphotericin B.
- the preparation must adhere to the nasal and oral mucous membranes, slowly release the antibiotics and have a surface tension allowing maximum spreading on the mucous membranes nasal and oropharyngeal.
- the preparation is administered by precise spraying either in the form of a pressurized aerosol dispensed by a continuous or metering valve or in the form of a nebulization dispensed by a precise pump.
- Two pushers are supplied with each bottle: one with a long and fine cannula allowing the introduction through the nostrils and the vaporization of the nasal passages, the other with a cannula allowing a broad vaporization of the oropharyngeal cavity .
- the doses dispensed by the valves or pumps will be very precise. They are of course a function of the concentration of antibiotics in the preparation.
- the frequency of applications also depends on the concentration of these products.
- valve or pump must be adapted to deliver 0.5 ml each time it is pressed.
- 400 mg of polymyxin B, 360 mg of tobramycin and 2000 mg of amphotericin B are administered daily.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR8714345 | 1987-10-19 | ||
| FR8714345A FR2621817B1 (fr) | 1987-10-19 | 1987-10-19 | Medicament comprenant l'association de polymyxine b, de tobramycine et d'amphotericine b administre par vaporisation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EP0338062A1 true EP0338062A1 (de) | 1989-10-25 |
Family
ID=9355910
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP19880909559 Ceased EP0338062A1 (de) | 1987-10-19 | 1988-10-19 | Durch sprühen verabreichtes arzneimittel auf basis einer kombination aus polymixin b, tobramycin und amphotericin b |
Country Status (4)
| Country | Link |
|---|---|
| EP (1) | EP0338062A1 (de) |
| AU (1) | AU2614088A (de) |
| FR (1) | FR2621817B1 (de) |
| WO (1) | WO1989003673A1 (de) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2290707A (en) * | 1994-06-28 | 1996-01-10 | Georgi Stankov | Pharmaceutical uses of Amphotericin B |
| GB2290708A (en) * | 1994-06-28 | 1996-01-10 | Georgi Stankov | Pharmaceutical uses of polyene macrolides |
| EP2077132A1 (de) | 2008-01-02 | 2009-07-08 | Boehringer Ingelheim Pharma GmbH & Co. KG | Abgabevorrichtung, Aufbewahrungsvorrichtung und Verfahren zur Abgabe einer Formulierung |
| US10011906B2 (en) | 2009-03-31 | 2018-07-03 | Beohringer Ingelheim International Gmbh | Method for coating a surface of a component |
| WO2010133294A2 (de) | 2009-05-18 | 2010-11-25 | Boehringer Ingelheim International Gmbh | Adapter, inhalationseinrichtung und zerstäuber |
| US10016568B2 (en) | 2009-11-25 | 2018-07-10 | Boehringer Ingelheim International Gmbh | Nebulizer |
| EA026241B1 (ru) | 2009-11-25 | 2017-03-31 | Бёрингер Ингельхайм Интернациональ Гмбх | Распылитель |
| JP5658268B2 (ja) | 2009-11-25 | 2015-01-21 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ネブライザ |
| WO2011160932A1 (en) | 2010-06-24 | 2011-12-29 | Boehringer Ingelheim International Gmbh | Nebulizer |
| WO2012130757A1 (de) | 2011-04-01 | 2012-10-04 | Boehringer Ingelheim International Gmbh | Medizinisches gerät mit behälter |
| US9827384B2 (en) | 2011-05-23 | 2017-11-28 | Boehringer Ingelheim International Gmbh | Nebulizer |
| WO2013152894A1 (de) | 2012-04-13 | 2013-10-17 | Boehringer Ingelheim International Gmbh | Zerstäuber mit kodiermitteln |
| EP3030298B1 (de) | 2013-08-09 | 2017-10-11 | Boehringer Ingelheim International GmbH | Vernebler |
| PL2835146T3 (pl) | 2013-08-09 | 2021-04-06 | Boehringer Ingelheim International Gmbh | Nebulizator |
| AU2015257878B2 (en) | 2014-05-07 | 2019-08-08 | Boehringer Ingelheim International Gmbh | Container, nebulizer and use |
| HUE055604T2 (hu) | 2014-05-07 | 2021-12-28 | Boehringer Ingelheim Int | Porlasztó |
| EA035261B1 (ru) | 2014-05-07 | 2020-05-21 | Бёрингер Ингельхайм Интернациональ Гмбх | Небулайзер и контейнер |
| WO2025137891A1 (zh) * | 2023-12-26 | 2025-07-03 | 苏州大学 | 一种联合复方药在病原细菌持留感染治疗中的应用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL121455C (de) * | 1900-01-01 | |||
| BE629985A (de) * | 1962-11-29 | |||
| AU539563B2 (en) * | 1981-01-21 | 1984-10-04 | Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara | Primycin, doxycyline and sisomicin composition |
-
1987
- 1987-10-19 FR FR8714345A patent/FR2621817B1/fr not_active Expired - Lifetime
-
1988
- 1988-10-19 WO PCT/FR1988/000513 patent/WO1989003673A1/fr not_active Ceased
- 1988-10-19 EP EP19880909559 patent/EP0338062A1/de not_active Ceased
- 1988-10-19 AU AU26140/88A patent/AU2614088A/en not_active Abandoned
Non-Patent Citations (1)
| Title |
|---|
| See references of WO8903673A1 * |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2614088A (en) | 1989-05-23 |
| FR2621817B1 (fr) | 1990-12-14 |
| FR2621817A1 (fr) | 1989-04-21 |
| WO1989003673A1 (fr) | 1989-05-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0338062A1 (de) | Durch sprühen verabreichtes arzneimittel auf basis einer kombination aus polymixin b, tobramycin und amphotericin b | |
| WO1989003672A1 (fr) | Medicament comprenant l'association de polymyxine b, de netilmicine et d'amphotericine b administre par vaporisation | |
| EP0390832A1 (de) | Arzneimittel mit einem gehalt an einer mischung von colistin, tobramycin und amphotericin b zur verabreichung durch verdampfung | |
| DE69532678D1 (de) | Arzneizubereitungen enthaltend nicht-steroidale entzündungshemmende Arzneimittel | |
| PT984762E (pt) | Configuracoes de controlador de debito para um dispositivo de administracao de agente activo | |
| GEP20043260B (en) | Aerosolized Active Agent Delivery and Device for Realization Thereof | |
| CA2039456A1 (en) | Osmotic dosage system for liquid drug delivery | |
| ATE138071T1 (de) | Lipidhilfstoffe für verabreichung durch die nase und örtliche anwendung | |
| NO912001L (no) | Buccal tablett med hurtig utlevering. | |
| ATE336986T1 (de) | Arzneimittel zur verabreichung auf schleimhäute | |
| DE69519685D1 (de) | Oral anzuwendende arzneizubereitung mit verzögerter wirkstoffabgabe | |
| US4876283A (en) | Antisnoring agent | |
| WO2002007810A3 (en) | Catheter for target specific drug delivery | |
| CA1223210A (en) | Antisnoring agent | |
| CA2433833A1 (en) | Use of flumazenil in developing a drug for the treatment of alcohol dependence | |
| BE900749A (fr) | Medicament microencapsule dans une matrice sucree. | |
| KR970032872A (ko) | 아세틸살리실산을 함유하는 피부 손상 처치용 약물 | |
| WO2003032946A3 (en) | Ph-sensitive liposomes for targeted drug delivery | |
| JP2002068963A (ja) | 液剤及び容器 | |
| CA2296231C (en) | Composition and method for treating common viral infections | |
| FR2624017A1 (fr) | Medicament comprenant l'association de colistine, d'amikacine et d'amphotericine b administre par vaporisation | |
| WO2002015940A3 (en) | Solution of an oxazolidinone antibiotic drug | |
| FR2622113A1 (fr) | Medicament comprenant l'association de polymyxine b, d'amikacine et d'amphotericine b administre par vaporisation | |
| FR2624739A1 (fr) | Medicament comprenant l'association de colistine, de neomycine et d'amphotericine b administre par vaporisation | |
| FR2624738A1 (fr) | Medicament comprenant l'association de colistine, de sisomicine et d'amphotericine b administre par vaporisation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH DE GB IT LI LU NL SE |
|
| 17P | Request for examination filed |
Effective date: 19890911 |
|
| 17Q | First examination report despatched |
Effective date: 19910404 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED |
|
| 18R | Application refused |
Effective date: 19910922 |